Towards sustainability and affordability of expensive cell and gene therapies? Applying a cost-based pricing model to estimate prices for Libmeldy and Zolgensma

Frederick W. Thielen(University Medical Center Freiburg), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Renske M.T. ten Ham(Leidsche Rijn Julius Health Centers), Renaud Heine(Erasmus University Rotterdam), Sibren van den Berg(Dutch Cancer Society)
Cytotherapy
October 7, 2022
Cited by 26


Related Papers